Post-Treatment Effects of Dipyridamole On Nucleoside Transport Inhibitio
Completed
- Conditions
- AtherosclerosisIschemia10003216
- Registration Number
- NL-OMON34866
- Lead Sponsor
- Pharmacology-Toxicology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 14
Inclusion Criteria
Healthy volunteers
Age 18-50
Written informed consent
Exclusion Criteria
Smoking
History of any cardiovascular disease
Asthma
Hypertension (in supine position: systole>140 mm Hg, diastole>90 mmHg)
Diabetes mellitus (fasting glucose >7.0 mmol/L or random glucose>11.0 mmol/L)
Concomitant use of medication
Alcohol or drug abuse
Women without appropriate anticonception
Participation to any drug-investigation during the previous 60 days as checked with VIP check
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Comparison of nucleoside uptake inhibition before, during (day 7), and after<br /><br>(day 14, 21, 28, and 35) treatment with dipyridamole between actively treated<br /><br>an control individuals at 35 days after start of the study (28 days after<br /><br>cessation of treatment in actively treated subjects).</p><br>
- Secondary Outcome Measures
Name Time Method <p>plasma and whole blood dipyridamole concentration</p><br>